^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Salivary Gland Cancer
    Drug:Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-TAT 2023
    Title:

    6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study

    Published date:
    03/02/2023
    Excerpt:
    As of 05 Jan 2023 (data cutoff), 1 patient achieved CR, 4 patients achieved PR, 4 patients achieved SD, and only 1 patient achieved PD. The overall confirmed DCR was 90%....RC48-ADC showed a promising efficacy with a manageable safety profile in HER2-expressing mSDC patients who had failed at least one line of systemic chemotherapy.